

I hereby certify that this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to:
Mail Stop Amendment, Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on this 19th day of November 2006.

By

(Signature of person mailing)
Erica L. Smith

(Typed or printed name of person)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Paul S. Changelian

Serial No.: 10/720,600

Filed: November 24, 2003

Title: METHOD OF TREATMENT OF
TRANSPLANT REJECTION

Group Art Unit: 1624

Examiner: V. Balasubramanian

Mail Stop Amendment
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Sir:

Applicant hereby submits to the U.S. Patent and Trademark Office form PTO-FB-A820 and a copy of certain documents cited therein to ensure compliance with the continuing duty of candor as set forth in 37 C.F.R. § 1.56. Applicant respectfully requests the Examiner carefully consider the complete text of the documents cited therein in connection with the examination of the above-identified application. This submission is intended to augment, and not replace, the Information Disclosure Statements filed previously on January 9, 2004 and March 19, 2004.

Applicant is not providing herewith a copy of the U.S. patents and U.S. patent application publications cited in form PTO-FB-A820 pursuant to 37 C.F.R. § 1.98(a)(2)(ii). Rather, Applicant is

providing herewith a copy of all foreign patents, publications, and unpublished U.S. applications cited in form PTO-FB-A820 pursuant to 37 C.F.R. §1.98(a)(2).

In particular, Applicant would like to draw the Examiner's attention to the following patents and patent applications cited in form PTO-FB-A820. To the extent any of the following applications issued as a U.S. patent, whose number is listed below, the corresponding U.S. application publication number was not cited in form PTO-FB-A820 since the disclosures of the U.S. patent and its corresponding U.S. application publication are substantively cumulative. 37 C.F.R. §1.98(c).

Attorney Docket Number	U.S. Serial No.	Filing Date	Title	U.S. Pub. No.	Pub. Date	U.S. Patent No.
PC10209A	09/335,030	06/17/99	Monocyclic-7H-Pyrrolo[2,3-D]Pyrimidine Compounds, Compositions, And Methods Of Use	N/A	N/A	6,635,762
PC10209B	10/640,079	08/13/03	Pyrrolo[2,3-D] Pyrimidine Compounds	2004-0058922	03/25/04	N/A
PC10285A	09/335,121	06/17/99	Pyrrolo[2,3-D] Pyrimidine Compounds	N/A	N/A	N/A
PC10285B	09/956,645	09/19/01	Pyrrolo[2,3-D] Pyrimidine Compounds	2002-0019526	02/14/02	6,610,847
PC10285C	10/442,807	05/20/03	Pyrrolo[2,3-D] Pyrimidine Compounds	2003-0212273	11/13/03	6,890,929
PC10285D	11/064,873	02/23/05	Pyrrolo[2,3-D] Pyrimidine Compounds	2005-0171128	08/04/05	N/A
PC10609A	09/732,669	12/08/00	Pyrrolo[2,3-D] Pyrimidine Compounds	2001-0053782	12/20/01	6,627,754
PC10609B	10/640,227	08/13/03	Pyrrolo[2,3-D] Pyrimidine Compounds	2004-0053947	08/12/04	6,956,041

PC10609C	11/211,217	08/24/05	Pyrrolo[2,3-D] Pyrimidine Compounds	2005-0288313	12/29/05	7,091,208
PC10609D	11/474,233	06/23/06	Pyrrolo[2,3-D] Pyrimidine Compounds	2006-024113	10/26/06	N/A
PC11027A	09/891,028	06/25/01	Pyrrolo[2,3-D] Pyrimidine Compounds	2002-0068746	06/06/02	6,696,567
PC11027B	10/463,724	06/16/03	Pyrrolo[2,3-D] Pyrimidine Compounds	2003-0220353	11/27/03	6,962,993
PC11027C	11/112,307	04/21/05	Pyrrolo[2,3-D] Pyrimidine Compounds	2005-0197349	09/08/05	N/A
PC23066A	10/154,699	05/23/02	CHIRAL SALT RESOLUTION	2003-0073719	04/17/03	N/A
PC23066B	10/869,101	06/15/04	CHIRAL SALT RESOLUTION	2004-0229923	11/18/04	N/A
PC23261A	10/310,078	12/04/02	NOVEL CRYSTALLINE COMPOUND	2003-0130292	07/10/03	6,965,027
PC23261B	11/032,990	01/10/05	NOVEL CRYSTALLINE COMPOUND	2005-0159434	07/21/05	N/A
PC32063A	11/011,474	12/13/04	Method Treatment Of Transplant Rejection	2005-0159433	07/21/05	N/A


In the judgment of the undersigned, portions of the documents cited in form PTO-FB-A820 may be material to the present application, however, the filing of this Information Disclosure Statement shall not be construed to be an admission that the documents cited are, or are considered to be, material with regard to patentability as defined in 37 C.F.R. § 1.56(b). The documents have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative importance of any portion of the documents. This statement is not a representation that the listed documents have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. § 102 or § 103.

Applicant requests the documents listed on attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

Because this Information Disclosure Statement is being filed after the mailing of a first Office Action on the merits and before the mailing of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that otherwise closes prosecution in the application, Applicant believes the fee set forth in § 1.17(p) is associated with the filing of this paper, which is detailed in the Fee Transmittal form filed herewith. 37 C.F.R. § 1.97(c). To the extent any additional fees are due, the Commissioner is hereby authorized to charge any fees or credit any overpayment to Account No. 16-1445.

Respectfully submitted,

Date: November 29, 2006



Christopher J. Verni
Attorney for Applicant
Reg. No. 48,322

Customer No. 28523
Pfizer Inc.
Patent Department, MS 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 686-2032

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC25530A	SERIAL NO. 10/720,600
	APPLICANT Paul S. Changelian, et al.	
	FILING DATE November 24, 2003	GROUP 1624

U.S. PATENT DOCUMENTS

EXAMINER INITIALS	DOCUMENT NUMBER								DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	3	0	3	7	9	8	0	6/5/62	Hitchings, et al.	260	256.4	
	US	5	2	7	2	1	4	7	12/21/93	Bell, et al.	514	234.2	
	US	5	3	8	9	5	0	9	2/14/95	Maskasky	430	567	
	US	5	4	9	6	9	4	6	3/5/96	Akimoto, et al.	544	321	
	US	5	6	8	6	4	5	7	11/11/97	Traxler, et al.	514	258	
	US	6	0	8	0	7	4	7	6/27/00	Uckun, et al.	514	259	
	US	6	1	3	6	5	9	5	10/24/00	Ihle, et al.	435	320.1	
	US	6	1	8	0	6	3	6	1/30/01	Traxler, et al.	514	258	
	US	6	1	8	7	5	5	2	2/13/01	Roberds, et al.	435	7.93	
	US	6	3	1	0	0	6	3	10/30/01	Ge, et al.	514	234.5	
	US	6	6	1	0	8	4	7	8/26/03	Blumenkopf, et al.	544	280	
	US	6	6	2	7	7	5	4	9/30/03	Blumenkopf, et al.	544	280	
	US	6	6	3	5	7	6	2	10/21/03	Blumenkopf, et al.	544	280	
	US	6	6	9	6	5	6	7	2/24/04	Blumenkopf, et al.	544	280	
	US	6	8	9	0	9	2	9	5/10/05	Blumenkopf, et al.	514	258	
	US	6	9	5	6	0	4	1	10/18/05	Blumenkopf, et al.	544	280	
	US	6	9	6	2	9	9	3	11/8/05	Blumenkopf, et al.	544	280	
	US	6	9	6	5	0	2	7	11/15/05	Flanagan, et al.	544	280	
	US	7	0	7	9	2	0	8	7/18/06	Kim, et al.	349	119	
	US	7	0	9	1	2	0	8	8/15/06	Blumenkopf, et al.	514	259.1	

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	EP	0	3	3	4	6	3	6	9/27/89	European	C07D	487/04		
	EP	0	6	8	2	0	2	7	10/15/97	European	C07D	487/04		
	EP	0	7	9	5	5	5	6	9/17/97	European	C07D	487/04		
	GB	0	9	1	5	3	0	3	1/9/63	Great Britain	C07D			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>						ATTY. DOCKET NO. PC25530A				SERIAL NO. 10/720,600			
						APPLICANT Paul S. Changelian, et al.							
						FILING DATE November 24, 2003				GROUP 1624			

	WO	9	5	1	9	7	7	4	7/27/95	International	A61K	31/505		
	WO	9	6	4	0	1	4	2	12/19/96	International	A61K	31/505		
	WO	9	7	0	2	2	6	2	1/23/97	International	C07D	401/12		
	WO	9	7	0	2	2	6	6	1/23/97	International	C07D	487/04		
	WO	9	7	1	3	7	7	1	4/17/97	International	C07D	471/04		
	WO	9	7	1	8	2	1	2	5/22/97	International	C07D	473/34		
	WO	9	7	2	7	1	9	9	7/31/97	International	C07D	487/04		
	WO	9	7	2	8	1	6	1	8/7/97	International	C07D	487/04		
	WO	9	7	3	2	8	7	9	9/12/97	International	C07D	487/0		
	WO	9	7	4	9	7	0	6	12/31/97	International	C07D	487/04		
	WO	9	8	0	2	4	3	7	1/22/98	International	C07D	471/04		
	WO	9	8	0	2	4	3	8	7/13/96	International	C07D	471/04		
	WO	9	8	0	7	7	2	6	2/26/98	International	C07D	487/04		
	WO	9	8	2	3	6	1	3	6/4/98	International	C07D	471/04		
	WO	9	8	3	3	7	9	8	8/6/98	International	C07D	471/00		
	WO	9	9	5	1	5	9	9	10/14/99	International	C07D	471/04		
	WO	9	9	6	1	4	2	8	12/2/99	International	C07D	239/94		
	WO	9	9	6	5	9	0	8	12/23/99	International	C07D	487/04		
	WO	9	9	6	5	9	0	9	12/23/99	International	C07D	487/04		
	WO	0	0	0	0	2	0	2	1/16/00	International	A61K	31/517		
	WO	0	0	1	0	9	8	1	3/2/00	International	C07D	239/94		
	WO	0	0	1	7	2	0	3	3/30/00	International	C07D	487/04		
	WO	0	1	4	2	2	4	6	6/14/01	International	A61K	487/04		
	WO	0	2	0	0	6	6	1	1/3/02	International	C07D	487/04		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)														
			Aringer, et al., <u>Life Sciences</u> , "Janus Kinases and Their Role in Growth and Disease", Vol. 64, No. 24, pages 2173-2186 (1999)											
			Baird, A.M., et al., <u>J. Leukocyte Biology</u> , "T Cell Development and Activation in JAK-3-Deficient Mice", Vol. 63, pages 669-672 (1998)											
			Candotti, F., et al., <u>Springer Semin. Immunopathology</u> , "Severe Combined Immune Deficiencies due to Defects in the Common											

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25530A	SERIAL NO. 10/720,600
			APPLICANT Paul S. Changelian, et al.	
			FILING DATE November 24, 2003	GROUP 1624
			y chain-JAK3 Signaling Pathway", Vol. 19, pages 401-415 (1998)	
			Chen, E., et al., <u>Transplantation Proceedings</u> , "Advances in Cytokine Signaling: The Role of JAKs and STATs", Vol. 31, pgs. 1482 - 1487 (1999)	
			Eynon, E.E., et al., <u>Journal of Interferon and Cytokine Research</u> , "Disruption of Cytokine Signaling in Lymphoid Development: Unique Contributions of the Common Cytokine Gamma Chain and the JAK3 Kinase", Vol. 16, pgs. 667-684 (1996)	
			Ghosh, S., et al., <u>Acta Crystallogr. C:Crystal. Structure Commun.</u> , "4-[(3-Bromo-4-hydroxyphenyl)amino]6,7-dimethoxyquinazolin-1-ium Chloride Methanol Solvate and 4-[(3-hydroxyphenyl)amino]6,7-dimethoxy-1-quinazolinium Chloride", Vol. C57, pages 76-78 (2001)	
			Hanke, J.H., et al., <u>Inflammation Research</u> , "Role of Tyrosine Kinases in Lymphocyte Activation: Targets for Drug Intervention", Vol. 44, pgs. 357-371 (1995)	
			Ihle, J.N., <u>Advance Immunology</u> , "The Janus Protein Tyrosine Kinase Family and Its Role in Cytokine Signaling", Vol. 60, page 1-35 (1995)	
			Ihle, J.N., <u>Semin. Immunology</u> , "The Janus Protein Tyrosine Kinases in Hematopoietic Cytokine Signaling", Vol. 7, page 247 (1995)	
			Kirken, R.A., et al., <u>Cytokine</u> , "Activation of JAK3, but not JAK1, is Critical for IL-2-Induced Proliferation and Stat 5 Recruitment by a CooH-Terminal Region of IL-2 Receptor β -Chain", Vol. 7, pgs. 689-700 (1995)	
			Leonard, W.J., et al., <u>Annual Review of Immunology</u> , "JAKs and STATs: Biological Implications", Vol. 16, pgs. 293-322 (1998)	
			Li, X.C., et al., <u>Journal of Immunology</u> , "Blocking the Common γ -Chain of Cytokine Receptors Induces T Cell Apoptosis and Long-term Islet Allograft Survival", Vol. 164, pages 1193-1199 (2000)	
			Liu, K.D., et al., <u>Current Opinion of Immunology</u> , "JAK/STAT Signaling By Cytokine Receptors", Vol. 10, pages 271-278 (1998)	
			Malaviya, R., et al., <u>J. Pharmacol. Exp. Ther.</u> , "Treatment of Allergic Asthma by Targeting Janus Kinase 3-Dependent Leukotriene Synthesis in Mast Cells with 4-[(3-hydroxyphenyl)amino]6,7-dimethoxyquinazoline (WHI-P97)", Vol. 295, page 912 (2000)	
			Malaviya, R., et al., <u>Biochemistry Biophysical Research Community</u> , "Genetic and Biochemical Evidence for a Critical Role of Janus Kinase (JAK)-3 in Mast Cell-Mediated Type 1 Hypersensitivity Reactions", Vol. 257, pgs. 807-813 (1999)	
			Malaviya, R., et al., <u>Journal of Biological Chemistry</u> , "Targeting Janus Kinase 3 in Mast Cells Prevents Immediate Hypersensitivity Reactions and Anaphylaxis", Vol. 274(38), pgs. 27028-27038 (1999)	
			Malabarba, M.G., et al., <u>Journal of Biological Chemistry</u> , "Activation of JAK3, but not JAK1, is Critical to Interleukin-4(IL4) Stimulated Proliferation and Requires a Membrane-Proximal Region of IL4 Receptor α ", Vol. 270(16), pgs. 9630-9637 (1995)	
			Moriggi, R., et al., <u>Immunity</u> , "Stat5 Activation is Uniquely Associated with Cytokine Signaling in Peripheral T Cells", Vol. 11, pgs. 225-230 (1995)	
			Musso, T., et al., <u>Journal of Experimental Medicine</u> , "Regulation of JAK3 Expression in Human Monocytes: Phosphorylation in Response to Interleukins 2, 4, and 7", Vol. 181, pages 1425-1431 (1995)	
			Nelson, B.H., et al., <u>Proceedings of National Academy of Science USA</u> , "Requirement for an Initial Signal from the Membrane-Proximal Region of the Interleukin 2 Receptor γ_c chain for Janus Kinase Activation Leading to T Cell Proliferation", Vol. 94, pgs. 1878-1883 (1997)	
			Notarangelo, L.D., et al., <u>Progressive Immunodeficiency</u> , "Severe Combined Immune Deficiency due to Defects of the JAK3 Tyrosine Kinase", Vol. 6, pgs. 61-68 (1996)	
			Oakes, S.A., et al., <u>Immunity</u> , "Signaling via IL-2and IL-4-JAK3-Deficient Severe Combined Immunodeficiency Lymphocytes: JAK3-Dependent and Independent Pathways", Vol. 5, pgs. 605-615 (1996)	

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)			ATTY. DOCKET NO. PC25530A	SERIAL NO. 10/720,600
			APPLICANT Paul S. Changelian, et al.	
			FILING DATE November 24, 2003	GROUP 1624
			O'Shea, J.J., et al., <u>Nature</u> , "Phosphorylation and Activation of the JAK-3 Janus Kinase in Response to Interleukin-2", Vol. 370(14), pages 151-153 (1994)	
			Russell, S.M., et al., <u>Science</u> , "Interaction of IL-2R β and γ_c Chains with JAK1 and JAK3: Implications for XSCID and XCID", Vol. 266, pages 1042-1045 (1994)	
			Shouda, et al., <u>The Journal of Clinical Investigation</u> , "Induction of the Cytokine Signal Regulator SOCS3/CIS3 as a Therapeutic Strategy for Treating Inflammatory Arthritis", Vol. 108(12) pages 1781-1788 (2001)	
			Sudbeck, E.A., et al., <u>Clinical Cancer Research</u> , "Structure-based Design of Specific Inhibitors of Janus Kinase 3 Apoptosis-Inducing Antileukemic Agents", Vol. 5, pages 1569-1582 (1999)	
			Sudbeck, E.A., et al., <u>IDrugs</u> , "Recent Advances in JAK3 Kinase Inhibitors", Vol. 2(10), pages 1026-1030 (1999)	
			Sudbeck, E.A., et al., <u>Acta Crystallogr., Sect C: Cryst. Struct. Commun.</u> , "An Inhibitor of Janus Kinase 3: 4-(4-hydroxyphenyl)amino-6,7-dimethoxyquinazolin-1-ium chloride", Vol. C56, pages 1282-1283 (2000)	
			Thomis, D.C., et al., <u>The Journal of Immunology</u> , "The JAK Family Tyrosine Kinase JAK3 is Required for IL-2 Synthesis by Naïve/Resting CD4 ⁺ T Cells", Vol. 163, pages 5411-5417 (1999)	
			Thomis, D.C., et al., <u>Journal of Experimental Medicine</u> , "Peripheral Expression of JAK3 is Required to Maintain T Lymphocyte Function", Vol. 185(2), pages 197-206 (1997)	
			Traxler, et al., <u>Experimental Opinion Therapeutic Pat.</u> , "Protein Tyrosine Kinase Inhibitors in Cancer Treatment", Vol. 7(6), pages 571-588 (1997)	
			Traxler, et al., <u>J. Med. Chem.</u> , "4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase", Vol. 39, pages 2285-2292 (1996)	
			Trieu, V.N., et al., <u>Biochemistry Biophysical Research Communications</u> , "A Specific Inhibitor of Janus Kinase-3 Increases Survival in a Transgenic Mouse Model of Amyotrophic Lateral Sclerosis", Vol. 267, pages 22-25 (2000)	
			Uckun, F.M., et al., <u>Clinical Cancer Research</u> , "In Vivo Toxicity and Pharmacokinetic Features of the Janus Kinase 3 Inhibitor WHI-P131 [40(4'-Hydroxyphenyl)-Amino-6,7-Dimethoxyquinazoline]", Vol. 5, pages 2954-2962 (1999)	
			Wang, L.H., et al., <u>Journal of Immunology</u> , "JAK3, STAT, and MAPK Signaling Pathways as Novel Molecular Targets for the Tyrphostin AG-490 Regulation of IL-2-Mediated T Cell Response", Vol. 162, page 3897 (1999)	
			US Serial No. 09/335,121 filed June 17, 1999 (PC10285A) Todd A. Blumenkopf	
			US Publication No. 2003-0073719 (Publication Date: 4/17/03) (PC23066A) Mark E. Flanagan	
			US Publication No. 2004-0229923 (Publication Date: 11/18/04) (PC23066B) Glenn E. Wilcox	
			US Publication No. 2004-0058922 (Publication Date: 3/25/04) (PC10209B) Todd A. Blumenkopf	
			US Publication No. 2004-0116449 (Publication Date: 6/17/04) (PC25530A) Paul Changelian	
			US Publication No. 2005-0197349 (Publication Date: 9/8/05) (PC11027C) Todd A. Blumenkopf	
			US Publication No. 2005-0171128 (Publication Date: 8/4/05) (PC10285D) Todd A. Blumenkopf	
			US Publication No. 2005-0159433 (Publication Date: 7/21/05) (PC32063A) Paul Changelian	
			US Publication No. 2005-0159434 (Publication Date: 7/21/05) (PC23261B) Mark E. Flanagan	

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			ATTY. DOCKET NO. PC25530A		SERIAL NO. 10/720,600	
			APPLICANT Paul S. Changelian, et al.			
			FILING DATE November 24, 2003		GROUP 1624	
			US Publication No. 2006-0241131 (Publication date: 10/26/06) (PC10609D) Todd A. Blumenkopf			
EXAMINER			DATE CONSIDERED			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE